Catalyst Wire Dossier Catalyst Wire Dossier

Zabedosertib

BAY1834845 · Bayer
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Zabedosertib, covering 2025-02-18 to 2025-02-18. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Learn How Well the Study Treatment Zabedosertib (BAY1834845) Works and How Safe it is Compared to Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis [Phase 2]

See pricing